Talaris Therapeutics Stock

talaristx.comHealthcareFounded: 1900Funding to Date: $100MM

Talaris Therapeutics is a late-clinical stage biotechnology company developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders.

Register for Details

For more details on financing and valuation for Talaris Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Talaris Therapeutics.

Register Today

Team

Management Team

Nancy Krieger MD
Chief Medical Officer
Francois Nader
Chairman
Suzanne Ildstad MD
Founder, Board Member & Chief Scientific Officer
Scott Requadt JD
Chief Executive Officer & Board Member

Board Members

Geoff MacKay
Sandip Agarwala
Longitude Capital
Mark McDade
Qiming Venture Partners
Scott Requadt JD
Suzanne Ildstad MD
Francois Nader
Nicholas Galakatos Ph.D
Blackstone Life Sciences

Other companies like Talaris Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B

News

The series A funding will be used to advance Talaris' proprietary, one-time, allogeneic cell therapy, FCR001, into later-stage clinical development.
Talaris Therapeutics, which develops cell therapies with potential to eliminate chronic immunosuppression for organ transplant recipients, raised $100m